In Faron’s case, we only ended up with such an unfavorable financing solution because first Markku, and then Juho, counted their chickens before they hatched. With hindsight, one could say that certain recruitments should have been made earlier. Still, it must be remembered that Faron has all along tried to advance—and is advancing—science. And that looks good. Now even the board’s former and biggest naysayers have quieted down. That’s probably some kind of sign too, isn’t it? The dilution is gruesome for old shareholders, while new investors are being offered potential upside on the cheap. Next year is make or break for Faron. It will be interesting to see if a Santa Claus rally materializes for Faron this year. For the first time, I doubt it will, unless ASH is convincing. Syrjälä’s increase hardly moved the share price anymore; an increase by the Jalkanens could have an impact. But those increases should be made now, or should have been made already—as long as no laws are broken in doing so. But let’s see these cards through to the end; after all, from the very beginning, this was always meant to be played as hit or miss, boom or bust. On the other hand, the most valuable things in the world are priceless, and if one can contribute to advancing human health, that certainly takes precedence over financial gains. It might save your life, my life, or the life of a loved one someday, and those things cannot be measured in money. If Faron goes under, let’s just chalk it up to charity. If not, the reward will be much more than just a financial return. Strange talk for an investment forum, but sometimes you have to pay back your own debts, and I’ll do it right here if needed.
19 Likes